Journal of drugs in dermatology : JDD · 2008
Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reytan Natalie, Rzany Berthold
Аннотация
BACKGROUND: Facial lipoatrophy is a common problem for patients with human immunodeficiency virus (HIV) treated with highly active antiretroviral therapy (HAART). The loss of subcutaneous facial tissue occurs in the cheeks, temples, and periocular region. Facial lipoatrophy is a stigmatizing feature of HIV. The effective treatment can provide psychosocial stress for the patient.
OBJECTIVE: To report on the experience using a novel porcine collagen filler in the treatment of a patient with HIV-associated facial lipoatrophy. Physician observations and photographs for documentation were collected up to 14 months posttreatment.
METHODS: A patient with HIV with facial lipoatrophy was treated with a novel collagen injectable filler derived from porcine collagen.
RESULTS: After 4 treatment sessions over 7 months using the novel porcine collagen injectable filler, significant improvement was found and dermal thickening was retained in the area of the cheeks for an additional 7 months.
CONCLUSION: As facial lipoatrophy is a very stigmatizing manifestation of HIV, volume augmentation is highly beneficial. Using a novel porcine collagen, a natural outcome was obtained that lasted for over 4 months. Additional studies should be conducted to further investigate the use of a novel porcine collagen in the treatment of HIV-associated facial lipoatrophy.
OBJECTIVE: To report on the experience using a novel porcine collagen filler in the treatment of a patient with HIV-associated facial lipoatrophy. Physician observations and photographs for documentation were collected up to 14 months posttreatment.
METHODS: A patient with HIV with facial lipoatrophy was treated with a novel collagen injectable filler derived from porcine collagen.
RESULTS: After 4 treatment sessions over 7 months using the novel porcine collagen injectable filler, significant improvement was found and dermal thickening was retained in the area of the cheeks for an additional 7 months.
CONCLUSION: As facial lipoatrophy is a very stigmatizing manifestation of HIV, volume augmentation is highly beneficial. Using a novel porcine collagen, a natural outcome was obtained that lasted for over 4 months. Additional studies should be conducted to further investigate the use of a novel porcine collagen in the treatment of HIV-associated facial lipoatrophy.